Aspirin In The Prevention Of Pre-Eclampsia: Where Are We Now?.pdf (124.68 kB)
0/0

Aspirin In The Prevention Of Pre-Eclampsia: Where Are We Now?

Download (124.68 kB)
journal contribution
posted on 22.11.2019 by A Khalid, Bridgette M. Byrne

Pre-eclampsia is a pregnancy specific multi-systemic disorder that causes maternal and perinatal morbidity and mortality worldwide. It is estimated to complicate between three to five percent of pregnancies and contributes to 8 to 10% of all preterm births1,2. Aspirin inhibits cyclooxygenase in platelets and endothelium in a fashion that alters the balance between the vasoconstrictor thromboxane and the vasodilator prostacyclin. This potentiates vasodilatation and reduces platelet aggregation, contributors to the endothelial dysfunction seen in preeclampsia. Over 100 clinical trials have examined whether or not Aspirin, when prescribed from early pregnancy, can prevent pre-eclampsia, and the consensus is that it reduces the incidence by approximately 10 to 24 % in women that are deemed to be at risk.

History

Comments

The original article is available at imj.ie

Published Citation

Khalid A, Byrne BM. Aspirin In The Prevention Of Pre-Eclampsia: Where Are We Now? Irish Medical Journal. 2018;111(3):704.

Publication Date

14/03/2018

Publisher

Irish Medical Organisation

PubMed ID

30376222

Exports

Logo branding

Exports